PATENT CLAIM ANALYSIS

Application Number: 15769308
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "339000"]

Abstract:
The present invention provides a pharmaceutical composition for use in treating acute myeloid leukemia (AML) and a method of treating AML in a patient in need thereof. The present invention also provides a method for predicting the sensitivity to the treatment in the patient using gene expression signature.

Claim (Index 9):
The pharmaceutical composition according to  claim 3 , wherein the patient has been predicted as being sensitive to the treatment by measuring the expression levels of at least one gene or all genes selected from the group of the genes below: BAX, RPS27L, XPC, DDB2, FDXR, MDM2, CDKN1A, AEN, RRM2B, SESN1, CCNG1, ZMAT3, and/or TNFRSF10B in a sample obtained from the patient.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 91.0
- Lexical Diversity: 1.52941
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12438944', '13950881', '14560519', '14430635', '15566336']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7593921531289521
- 35 USC 102 Novelty (BERT): 0.5719246615689784
- Combined Prediction Score: 0.7406454039729549
- Mean Citation Score: 388.860316
- Max Citation Score: 521.67804
- Similarity Product: 313.47934746080875

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test